Emad Kandil, MD, FACS, FACE
Dr. Kandil is an associate professor of surgery, and Otolaryngology (adjunct), the Edward G. Schlieder Chair in Surgical Oncology and the Chief of Endocrine Surgery sections at Tulane University Medical School, New Orleans, LA. He completed his training with a clinical fellowship in endocrine surgery at Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Kandil has written more than 150 original articles, invited reviews and book chapters and served on numerous editorial boards and committees. His research interests have focused on clinical outcome research related to endocrine surgery patients. His laboratory research focuses on examining the anti-tumor efficacies of multiple pathways targeting advanced thyroid cancer.
Xi-ru Li, MD
Dr. Li graduated from the Department of Clinical Medicine of the First Military Medical University in 1989 with a bachelor degree. He worked in the Department of General Surgery, Tang Du Hospital, Fourth Military Medical University, from 1989 to 2000, during which he received his master degree and was trained as attending physician and lecturer. He joined the Department of General Surgery of PLA General Hospital in September 2000. Currently he acts as the Deputy Executive Director of the Department of General Surgery and also is the Chief of the Department of Breast Surgery in PLA General Hospital.
He acts as a consultant for China National Drug and Food Administration new drug evaluation, vice Chairman of Military Breast and Endocrine Surgery Society, member of the Military General Surgery Society, member of Chinese Society of Clinical Oncology Breast Cancer Group, and member of Chinese Medical Doctor Association Breast Disease Group. He is the member of the editorial boards of several journals including Chinese Journal of Breast Disease.
He has published 60 plus papers in domestic and international journals. He has obtained a national invention patent. He is the responsible person for the following key research projects: "Application of Proteomics Technology in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer" (MA245), supported by the “11th Five-Year Plan” Military Health Research Fund; "Application of FISH Technology for the Detection of Breast Cancer HER-2 Gene (2007)", supported by the Ministry of Health; "Application of Magnetic Resonance Image Reconstruction and Simulated Surgery in the Breast-conserving Surgery for Patients with Breast Cancer - Breast Precision Surgical Technology" (2010gxjs092), supported by the Military Clinical High-Tech Key Program; and "Application of iTRAQ Proteomics Technology in Analyzing the Changes of the Protein Expressions after Neoadjuvant Chemotherapy for Breast Cancer" (2011), supported by the National Natural Science Fund. Meanwhile, he has participated in many other studies supported by the National "973 Program", "863 Program", and Beijing Municipal Key Program. He has co-authored several books.
He has accumulated rich experiences in medical care, teaching, and relevant research in the past two decades. Under his leadership, a multi-discipline team, known as "Breast Disease Diagnosis and Treatment Cooperative Team of PLA General Hospital" and participated by the Department of Surgery, Department of Oncology, Department of Pathology, Department of Radiotherapy, Dpartment of Ultrasound, Mammography room, and MRI room, has been established. Doctors who are involved in the management of breast diseases from different departments participate in this team and conduct academic activities regularly. Dr. Li has rich experiences in the early screening, etiological analysis, and clinical treatment of breast tumors. He plays a leading role in the management of clinically non-palpable breast cancer in China and keeps close contact with his international colleagues. He introduced the technique of magnetic resonance (MR)-guided biopsy into China and pioneered the application of intra-operative radiotherapy in the breast-conserving surgery for patients with breast cancer. He is also actively involved in the introduction of sentinel lymph node biopsy, phase I and phase II breast reconstruction after surgery for breast cancer, mastectomy (SSM) with conservation of the nipple-areola complex, implants reconstruction, and Mammotome minimally invasive breast surgery. Furthermore, he has standardized the multi-discipline breast-conserving treatment procedures, established a DNA bank for patients with breast cancer, and conducted pre-clinical and clinical research on pharmacogenomics-guided individualized treatment for breast cancer.
Zhiming Wang, MD, Ph.D
Dr. Wang is currently a professor and a doctoral supervisor at the Department of Surgery, Xiangya Hospital Central South University, Hunan, China. As a Director of the Liver and Thyroid Surgery, and vice Director of Organ Transplantation Center, he acts as the head of the Department of Surgery and General Surgery in the Xiangya Hospital.
Dr. Wang has earned various professional and academic titles such as the Editor-in-Chief of the Chinese Journal of General Surgery, Vice Leader of the Serious Infection Group of Surgical Branch of Chinese Medical Association, Committee Member of Liver Cancer Group of Oncological Branch of Chinese Medical Association, Committee Member of the Liver Cancer Specialized Committee of Chinese Anti-Cancer Association, Standing Committee Member of Liver Surgeon Committee of Surgical Branch of Chinese Medical Doctor Association, Committee Member of International Hepato-Pancreato-Biliary Association, Chairman of Hunan General Surgery Specialized Committee, Vice Chairman of Hunan Oncological Surgery Specialized Committee, and Vice Leader of Hunan Thyroid and Breast Surgery Group.
Dr. Wang graduated from the Department of Medicine, Hunan Medical University in 1984 with MD and in 1992 with Ph.D. He is also the author or co-author of over 10 books and textbooks in the field of general surgery. More than 80 articles have been published in domestic and international journals.